Researchers have developed an electronic medical record (EMR)–based model to enhance postpartum cardiovascular health (CVH) screening in women with hypertensive disorders of pregnancy (HDP). The findings were presented at ACC.25.
Advertisement
A study shows geographic disparities that exist as they pertain to heart failure mortality and its association with obesity.
The platform features incubation technology able to replicate cell microenvironments associated with SCD sickling.
ALS Functional Rating Scale-Revised results scores were used to determined therapeutic efficacy versus placebo.
Researchers examined factors associated with adherence to the urate-lowering therapy allopurinol.
A study examined one medical center's adherence to gout management guidelines regarding use of ULT to lower uric acid levels.
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
PEGS were developed from whole-blood DNA methylation samples for items such as blood pressure, BMI, and C-reactive protein.
The FDA granted orphan drug designation to rilzabrutinib for warm autoimmune hemolytic anemia and and IgG4-related disease.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
The platform features incubation technology able to replicate cell microenvironments associated with SCD sickling.
The FDA granted orphan drug designation to rilzabrutinib for warm autoimmune hemolytic anemia and and IgG4-related disease.
ASH Awards Commitee Chair Ivan Maillard, MD, PhD, and prior awardee Rinku Majumder, PhD, tell of the Grant's positive impact.
Bexobrutideg, an orally bioavailable, brain-penetrant BTK degrader, is being evaluated in a phase 1a/b study.
The agent recalibrates the immune system to attack tumors and increases cancer susceptibility to standard of care therapy.
Investigational T-Cell Immunotherapy Superior to Standard HSCT in Rate of Survival Plus GvHD Freedom
A phase 3 study comparing the treatments in multiple hematologic malignancies also saw greater overall survival at one year.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.